NextCell Pharma AB (FRA:65G)

Market Cap	13.75M -10.5%
Revenue (ttm)	998.29K -1.9%
Net Income	-3.17M
EPS	-0.04
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.1076
Previous Close	0.0994
Day's Range	0.1076 - 0.1076
52-Week Range	0.0462 - 0.2940
Beta	n/a
RSI	61.43
Earnings Date	Feb 3, 2026

About NextCell Pharma AB

NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. Its lead drug candidate is ProTrans, a cell therapy with mesenchymal stromal cells for the treatment of autoimmune and inflammatory diseases, including type-1 diabetes. The company also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is headquartered in Huddinge, Sweden.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2014
• Employees: 24
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 65G

Financial Performance

In fiscal year 2025, NextCell Pharma AB's revenue was 11.06 million, a decrease of -1.90% compared to the previous year's 11.28 million. Losses were -35.14 million, -16.25% less than in 2024.

Financial numbers in SEK